Exact Therapeutics AS (EXTX) — Cash Flow-to-Debt Ratio
Exact Therapeutics AS (EXTX) has a Cash Flow-to-Debt Ratio of -2.14x as of December 2024, meaning its operating cash flow of Nkr-80.55 Million could theoretically repay -2% of its total liabilities (Nkr37.65 Million) in one year. See working capital to net assets of Exact Therapeutics AS to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Exact Therapeutics AS Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for Exact Therapeutics AS across 8 annual periods. Also explore Exact Therapeutics AS (EXTX) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Exact Therapeutics AS (2017–2024)
Year-by-year debt coverage analysis for Exact Therapeutics AS. For market capitalisation and broader financial context, see Exact Therapeutics AS (EXTX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.14x | Nkr-80.55 Million | Nkr37.65 Million | ▲ +21.7% |
| 2023 | -2.73x | Nkr-44.30 Million | Nkr16.22 Million | ▼ -40.4% |
| 2022 | -1.95x | Nkr-33.85 Million | Nkr17.40 Million | ▲ +58.0% |
| 2021 | -4.64x | Nkr-55.11 Million | Nkr11.89 Million | ▼ -88.7% |
| 2020 | -2.46x | Nkr-25.99 Million | Nkr10.58 Million | ▼ -94.5% |
| 2019 | -1.26x | Nkr-12.46 Million | Nkr9.87 Million | ▲ +37.5% |
| 2018 | -2.02x | Nkr-12.46 Million | Nkr6.17 Million | ▼ -89.2% |
| 2017 | -1.07x | Nkr-12.46 Million | Nkr11.68 Million | — |